According to the World Health Organization, cardiovascular diseases are the major cause worldwide of mortality and morbidity, taking approximately 17.9 million lives each year. Current therapies are focused on protecting the heart from the progression of the disease rather than inducing myocardial regeneration and facilitating self-repair. Nevertheless, many strategies for therapeutic regeneration are being developed in order to achieve long-term functional stabilization and improvement in the heart function. One of these involves the use of injectable hydrogels as carriers of nanoparticles or bioactive molecules aiming to restore the cardiomyocytes functionality. Alginate-based hydrogels have reached clinical trials in cardiac applications because of their high biocompatibility and promising results by improving cardiac tissue remodelling.